Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$4.85 USD
-0.24 (-4.72%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $4.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Income Statements
Fiscal Year end for Lifecore Biomedical, Inc falls in the month of May .
All items in Millions except EPS data.
5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 | |
---|---|---|---|---|---|
Sales | NA | 103 | 186 | 544 | 590 |
Cost Of Goods | NA | 75 | 135 | 463 | 515 |
Gross Profit | NA | 28 | 50 | 81 | 75 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 50 | 92 | 95 | 114 |
Income After Depreciation & Amortization | 0 | -22 | -41 | -14 | -39 |
Non-Operating Income | NA | -24 | 7 | -12 | -3 |
Interest Expense | NA | 18 | 17 | 15 | 10 |
Pretax Income | NA | -64 | -52 | -40 | -51 |
Income Taxes | NA | 0 | -6 | -8 | -13 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -64 | -46 | -33 | -38 |
Extras & Discontinued Operations | NA | -35 | -51 | 0 | 0 |
Net Income (GAAP) | NA | -100 | -97 | -33 | -38 |
Depreciation Footnote | 5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -7 | 37 | 6 | -20 |
Depreciation & Amortization (Cash Flow) | NA | 15 | 79 | 20 | 19 |
Income After Depreciation & Amortization | 0 | -22 | -41 | -14 | -39 |
Earnings Per Share Data | 5/31/24 | 5/31/23 | 5/31/22 | 5/31/21 | 5/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 29.96 | 29.47 | 29.29 | 29.16 |
Diluted EPS Before Non-Recurring Items | NA | -1.52 | 0.90 | -0.08 | -0.26 |
Diluted Net EPS (GAAP) | NA | -3.32 | -3.31 | -1.12 | -1.31 |
Fiscal Year end for Lifecore Biomedical, Inc falls in the month of May .
All items in Millions except EPS data.
5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | -6.49 |
Cost Of Goods | NA | NA | NA | NA | -15.57 |
Gross Profit | NA | NA | NA | NA | 9.08 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 5.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 3.96 |
Non-Operating Income | NA | NA | NA | NA | -24.12 |
Interest Expense | NA | NA | NA | NA | 3.93 |
Pretax Income | NA | NA | NA | NA | -24.09 |
Income Taxes | NA | NA | NA | NA | 0.17 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | NA | NA | -24.26 |
Extras & Discontinued Operations | NA | NA | NA | NA | -10.60 |
Net Income (GAAP) | NA | NA | NA | NA | -34.86 |
Earnings Per Share Data | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 30.32 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | -0.89 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | -1.16 |